Choosing between Stereotactic and Hypofractionated Radiotherapy for inoperable Stage I NSCLC, summarised by Gustavo Viani

Gustavo Viani, Associate Professor, Faculdade de Medicina de Ribeirão Preto (FMRP) da USP, shared a post on LinkedIn:

“SBRT resulted in acceptable tumor control compared with CRT with limited toxic effects in lung cancer‼️

-Design
– Phase 3 RCT comparing SBRT and CRT for medically inoperable stage I NSCLC
– 233  randomized 2:1 to SBRT (154) or CRT (79)
– SBRT doses: 48 Gy (4 fractions) for peripheral NSCLC and 60 Gy (8 fractions) for central NSCLC
– CRT dose: 60 Gy (15 fractions).

Results:
-3-year local control 87.6% SBRT vs. 81.2% fCRT (HR, 0.61; P = .15)
– Minimal acute toxic effects; grade 5 hemoptysis occurred in 1 SBRT patient

Conclusion:
SBRT showed slightly local control, but No significant survival benefit.”

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung CancerThe LUSTRE Phase 3 Randomized Clinical Trial

Authors: Anand Swaminath, et al.

Source: Gustavo Viani/LinkedIn